Q-omics provides the consensus-scored RPL36AP15 profile across patient tissues and cancer cell-line models. RPL36AP15 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL36AP15 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, RPL36AP15 RNA expression shows 16,107 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where RPL36AP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP15 survival associations across molecular data types. RPL36AP15 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP15 RNA expression–survival associations across cancer types. High RPL36AP15 expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRC, DLBC, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL36AP15 RNA expression.
This table summarizes RPL36AP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP15 shows lower tumor expression in THCA, UCEC, BRCA and LUAD and higher tumor expression in KIRC. The THCA box plot shows higher RPL36AP15 RNA expression in normal versus tumor tissue (log2 FC = −0.292, t-test p < 0.001).
This table shows molecular features associated with RPL36AP15 in patient tissues and cancer cell lines. In patient samples, RPL36AP15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
